Experienced in Ewing Sarcoma

Dr. Joseph Chao

Oncology | Hematology | Hematology Oncology
1500 Duarte Rd, 
Duarte, CA 
Clinical Trials:Currently Recruiting for 1 Trial
Experienced in Ewing Sarcoma
1500 Duarte Rd, 
Duarte, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Joseph Chao is an Oncologist and a Hematologist in Duarte, California. Dr. Chao is rated as an Experienced provider by MediFind in the treatment of Ewing Sarcoma. His top areas of expertise are Stomach Cancer, Colorectal Cancer, Gastroesophageal Junction Cancer, Endoscopy, and Tissue Biopsy.

His clinical research consists of co-authoring 112 peer reviewed articles and participating in 15 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article and participated in 1 clinical trial in the study of Ewing Sarcoma.

Specialties
Oncology
Hematology
Hematology Oncology
Licenses
Internal Medicine in CA
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID

Locations

1500 Duarte Rd, Duarte, CA 91010

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

15 Clinical Trials

An Open-Label, Multicenter, First-in-Human, Phase 1 Dose-Escalation and Multicohort Expansion Study of INBRX-109 in Subjects with Locally Advanced or Metastatic Solid Tumors Including Sarcomas
An Open-Label, Multicenter, First-in-Human, Phase 1 Dose-Escalation and Multicohort Expansion Study of INBRX-109 in Subjects with Locally Advanced or Metastatic Solid Tumors Including Sarcomas
Enrollment Status: Recruiting
Publish Date: December 12, 2024
Intervention Type: Drug
Study Drugs: INBRX-109 Tetravalent DR5 Agonist Antibody, Carboplatin, Cisplatin, Pemetrexed, 5-Fluorouracil, Irinotecan
Study Phase: Phase 1
A Phase 1/2 Study of Olaparib in Combination With Ramucirumab in Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma (10017760)
A Phase 1/2 Study of Olaparib in Combination With Ramucirumab in Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma (10017760)
Enrollment Status: Completed
Publish Date: September 16, 2025
Intervention Type: Biological, Drug
Study Drugs: Olaparib, Ramucirumab
Study Phase: Phase 1/Phase 2
A Phase 2 Trial of Neoadjuvant Chemoradiation With Pembrolizumab Followed by Pembrolizumab With Lenvatinib in Esophageal/Gastroesophageal Junction Squamous Cell and Adenocarcinomas
A Phase 2 Trial of Neoadjuvant Chemoradiation With Pembrolizumab Followed by Pembrolizumab With Lenvatinib in Esophageal/Gastroesophageal Junction Squamous Cell and Adenocarcinomas
Enrollment Status: Active_not_recruiting
Publish Date: September 04, 2025
Intervention Type: Procedure, Drug, Radiation, Biological
Study Drugs: Carboplatin, Lenvatinib Mesylate, Paclitaxel, Pembrolizumab
Study Phase: Phase 2
A Phase 2 Single-Arm Study of M6620 in Combination With Irinotecan in Patients With Progressive TP53 Mutant Gastric and Gastro-Esophageal Junction Cancer
A Phase 2 Single-Arm Study of M6620 in Combination With Irinotecan in Patients With Progressive TP53 Mutant Gastric and Gastro-Esophageal Junction Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 30, 2025
Intervention Type: Procedure, Drug
Study Drugs: Berzosertib, Irinotecan
Study Phase: Phase 2
A Phase I, Dose-Escalation, Safety and Tolerability Study of COH29 in Patients With Solid Tumors Refractory to Standard Therapy or for Which No Standard Therapy Exists
A Phase I, Dose-Escalation, Safety and Tolerability Study of COH29 in Patients With Solid Tumors Refractory to Standard Therapy or for Which No Standard Therapy Exists
Enrollment Status: Active_not_recruiting
Publish Date: July 04, 2025
Intervention Type: Other, Drug
Study Phase: Phase 1
A Randomized, Double-blind, Placebo-controlled, Active Comparator Phase 2/3 Study of Tucatinib in Combination With Trastuzumab, Ramucirumab, and Paclitaxel in Subjects With Previously Treated, Locally-advanced Unresectable or Metastatic HER2+ Gastric or Gastroesophageal Junction Adenocarcinoma (GEC)
A Randomized, Double-blind, Placebo-controlled, Active Comparator Phase 2/3 Study of Tucatinib in Combination With Trastuzumab, Ramucirumab, and Paclitaxel in Subjects With Previously Treated, Locally-advanced Unresectable or Metastatic HER2+ Gastric or Gastroesophageal Junction Adenocarcinoma (GEC)
Enrollment Status: Completed
Publish Date: January 22, 2025
Intervention Type: Drug, Other
Study Drugs: Tucatinib, Trastuzumab, Ramucirumab, Paclitaxel
Study Phase: Phase 2/Phase 3
Phase I/Ib Trial of ATR Inhibitor BAY 1895344 in Combination With FOLFIRI in GI Malignancies With a Focus on Metastatic Colorectal and Gastric/Gastroesophageal Cancers
Phase I/Ib Trial of ATR Inhibitor BAY 1895344 in Combination With FOLFIRI in GI Malignancies With a Focus on Metastatic Colorectal and Gastric/Gastroesophageal Cancers
Enrollment Status: Active_not_recruiting
Publish Date: October 10, 2024
Intervention Type: Procedure, Drug
Study Drugs: Elimusertib, Fluorouracil, Irinotecan Hydrochloride, Leucovorin Calcium
Study Phase: Phase 1
A Phase 2 Open-Label Clinical Trial of ADP-A2M4CD8 in Subjects With Advanced Esophageal or Esophagogastric Junction Cancers
A Phase 2 Open-Label Clinical Trial of ADP-A2M4CD8 in Subjects With Advanced Esophageal or Esophagogastric Junction Cancers
Enrollment Status: Terminated
Publish Date: September 04, 2024
Intervention Type: Genetic
Study Phase: Phase 2
A Phase 1 Open-Label, Dose-Finding Study Evaluating Safety and Pharmacokinetics of FPA144 in Patients With Advanced Solid Tumors
A Phase 1 Open-Label, Dose-Finding Study Evaluating Safety and Pharmacokinetics of FPA144 in Patients With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: June 04, 2024
Intervention Type: Drug
Study Phase: Phase 1
A Phase I, First-in-Human, Open-Label, Dose Escalation and Expansion Study of TPX4589 in Patients With Claudin(CLDN)18.2-Positive Advanced Solid Tumors
A Phase I, First-in-Human, Open-Label, Dose Escalation and Expansion Study of TPX4589 in Patients With Claudin(CLDN)18.2-Positive Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: April 17, 2024
Intervention Type: Drug
Study Phase: Phase 1
Combining Pembrolizumab and Palliative Radiotherapy in Gastroesophageal Cancer to Enhance Anti-Tumor T Cell Response and Augment the Abscopal Effect
Combining Pembrolizumab and Palliative Radiotherapy in Gastroesophageal Cancer to Enhance Anti-Tumor T Cell Response and Augment the Abscopal Effect
Enrollment Status: Completed
Publish Date: February 20, 2024
Intervention Type: Other, Radiation, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 2
A Single Arm, Multi-center Phase 2 Trial of mFOLFOX6 + Trastuzumab + Avelumab in First-line, Metastatic, HER2-amplified Gastric and Esophageal Adenocarcinomas
A Single Arm, Multi-center Phase 2 Trial of mFOLFOX6 + Trastuzumab + Avelumab in First-line, Metastatic, HER2-amplified Gastric and Esophageal Adenocarcinomas
Enrollment Status: Completed
Publish Date: December 19, 2023
Intervention Type: Drug
Study Drugs: Oxaliplatin, Leucovorin, 5 fluorouracil, Trastuzumab, Avelumab
Study Phase: Phase 2
A Phase 1b/2 Trial of the IRX-2 Regimen and Pembrolizumab in Patients With Advanced Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma
A Phase 1b/2 Trial of the IRX-2 Regimen and Pembrolizumab in Patients With Advanced Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma
Enrollment Status: Completed
Publish Date: March 23, 2023
Intervention Type: Drug, Biological
Study Drugs: Cyclophosphamide, Cytokine-based Biologic Agent IRX-2, Pembrolizumab
Study Phase: Phase 1/Phase 2
An Open Label Phase 1B/2 Trial of TRC105 and Sorafenib in Patients With Hepatocellular Carcinoma (HCC)
An Open Label Phase 1B/2 Trial of TRC105 and Sorafenib in Patients With Hepatocellular Carcinoma (HCC)
Enrollment Status: Completed
Publish Date: July 17, 2020
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
Randomized Phase 2 Trial Evaluating Alternative Ramucirumab Doses in Combination With Paclitaxel in Second-Line Metastatic or Locally Advanced, Unresectable Gastric or Gastroesophageal Junction Adenocarcinoma
Randomized Phase 2 Trial Evaluating Alternative Ramucirumab Doses in Combination With Paclitaxel in Second-Line Metastatic or Locally Advanced, Unresectable Gastric or Gastroesophageal Junction Adenocarcinoma
Enrollment Status: Completed
Publish Date: June 17, 2020
Intervention Type: Drug
Study Phase: Phase 2
View 14 Less Clinical Trials

112 Total Publications

Overall Survival Analysis of the Phase III CodeBreaK 300 Study of Sotorasib Plus Panitumumab Versus Investigator's Choice in Chemorefractory KRAS G12C Colorectal Cancer.
Overall Survival Analysis of the Phase III CodeBreaK 300 Study of Sotorasib Plus Panitumumab Versus Investigator's Choice in Chemorefractory KRAS G12C Colorectal Cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: April 11, 2025
Similar Doctors
Elite in Ewing Sarcoma
Dr. Sant P. Chawla
Oncology | Hematology
Elite in Ewing Sarcoma
Dr. Sant P. Chawla
Oncology | Hematology
2811 Wilshire Boulevard, Suite 414, 
Santa Monica, CA 
 (29.5 miles away)
310-552-9999
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Sant Chawla is a Hematologist and an Oncologist in Santa Monica, California. Dr. Chawla is rated as an Elite provider by MediFind in the treatment of Ewing Sarcoma. His top areas of expertise are Adult Soft Tissue Sarcoma, Liposarcoma, Synovial Sarcoma, and Myxoid Liposarcoma. Dr. Chawla is currently accepting new patients.

Distinguished in Ewing Sarcoma
Dr. James Hu
Oncology | Hematology | Hematology Oncology
Distinguished in Ewing Sarcoma
Dr. James Hu
Oncology | Hematology | Hematology Oncology

USC Care Medical Group Inc

1441 Eastlake Ave, Suite 2424, 
Los Angeles, CA 
 (14.1 miles away)
323-442-2582
Languages Spoken:
English
See accepted insurances
Offers Telehealth

James Hu is an Oncologist and a Hematologist in Los Angeles, California. Dr. Hu is rated as an Elite provider by MediFind in the treatment of Ewing Sarcoma. His top areas of expertise are Adult Soft Tissue Sarcoma, Alveolar Soft Part Sarcoma, Synovial Sarcoma, and Liposarcoma.

Distinguished in Ewing Sarcoma
Dr. Warren Chow
Hematology | Oncology
Distinguished in Ewing Sarcoma
Dr. Warren Chow
Hematology | Oncology

Uc Regents

101 The City Dr S, Uci Dept Of Medicine, 
Orange, CA 
 (24.0 miles away)
714-456-7004
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Warren Chow is a Hematologist and an Oncologist in Orange, California. Dr. Chow is rated as an Elite provider by MediFind in the treatment of Ewing Sarcoma. His top areas of expertise are Adult Soft Tissue Sarcoma, Synovial Sarcoma, Liposarcoma, and Chondrosarcoma.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Chao's expertise for a condition
ConditionClose
View All 68 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile